Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Harvard Medical School / Harvard Pilgrim Health Care Institute | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
This nationally representative randomized survey of US adults will evaluate the effect of using brief statements to communicate multiple different sources of uncertainties about the benefits and harms of new cancer drugs on participants' decisions.
Many newer cancer drugs are approved before uncertainties with their underlying clinical trial evidence have been adequately studied, in turn making it difficult to accurately determine the drug's benefits and harms. Prescription drug information rarely communicates these uncertainties. In a nationally representative sample of US adults, this study will evaluate the effect of using brief statements to communicate multiple different sources of uncertainties about the benefits and harms of new cancer drugs on participants' decisions.
In the pre-intervention phase, participants will be given information about a hypothetical new drug approved for the treatment of non-small cell lung cancer. Participants will be asked how likely they would be to take the drug, and how certain they are that the drug will work. Participants will then be randomized with equal allocation to 1 of 5 groups. The control group will receive information about a new cancer drug's benefits and harms; the intervention groups will also be given brief statements about sources of uncertainties with the drug's evidence (1, 2, 3, or 4 sources of uncertainties). The post-intervention questions will re-assess participants' decision making, perceptions of uncertainty, emotions, understanding, and trust.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control group | Placebo Comparator | No information about uncertainty given. |
|
| 1 source of uncertainty | Experimental | Other: Statement communicating uncertainty with small magnitude of benefit |
|
| 2 sources of uncertainties | Experimental | Other: Statements communicating uncertainty with a small magnitude of benefit and limited study population |
|
| 3 sources of uncertainties | Experimental | Other: Statements communicating uncertainty with a small magnitude of benefit, limited study population, and unvalidated surrogate endpoint |
|
| 4 sources of uncertainties | Experimental | Other: Statements communicating uncertainty with a small magnitude of benefit, limited study population, unvalidated surrogate endpoint, and limited study duration. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Statement communicating 1 source of uncertainty | Other | It is unknown whether patients with non-small cell lung cancer will notice an improvement with Zenova. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in decisions | "Imagine you were Alex and diagnosed with non-small cell lung cancer. How likely are you to take the new drug, Zenova?" 4-point Likert scale for decision-making: very likely; somewhat likely; somewhat unlikely; very unlikely | Immediately prior to and after the intervention. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in understanding | Please answer rate your agreement with the following statements: Zenova works better than other treatments for non-small cell lung cancer Zenova's longer-term benefits and harms are well known Zenova has been studied in patients that are similar to Alex (race and ethnicity) Zenova improves how patients feel or how long they live Zenova has a very large benefit for patients with non-small cell lung cancer 4-point Likert scale for understanding: strongly disagree; somewhat disagree; somewhat agree; strongly agree. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| London School of Economics and Political Science | London | United Kingdom |
Not provided
| Label | URL |
|---|---|
| This is the second of 2 studies on communicating uncertainties associated with the benefits and risks of new cancer drugs | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP_ICF | Yes | Yes | Yes | Study Protocol, Statistical Analysis Plan, and Informed Consent Form | Jul 17, 2025 |
Not provided
Not provided
Not provided
Not provided
Not provided
| Statements communicating 2 sources of uncertainties | Other | It is unknown whether patients with non-small cell lung cancer will notice an improvement with Zenova. Zenova has not been studied in patients similar to Alex (patients with her race and ethnicity). It is unknown whether Zenova will work and what harms it will have for patients like her. |
|
| Statements communicating 3 sources of uncertainties | Other | It is unknown whether patients with non-small cell lung cancer will notice an improvement with Zenova. Zenova has not been studied in patients similar to Alex (patients with her race and ethnicity). It is unknown whether Zenova will work and what harms it will have for patients like her. Zenova has only been shown to shrink the size of tumors. It is unknown whether Zenova improves how patients feel or how long they live. |
|
| Statements communicating 4 sources of uncertainties | Other | It is unknown whether patients with non-small cell lung cancer will notice an improvement with Zenova. Zenova has not been studied in patients similar to Alex (patients with her race and ethnicity). It is unknown whether Zenova will work and what harms it will have for patients like her. Zenova has only been shown to shrink the size of tumors. It is unknown whether Zenova improves how patients feel or how long they live. Since patients given Zenova were followed for a short time, the longer-term benefits and harms of taking Zenova are unknown. |
|
| Control group | Other | No information about uncertainty |
|
| Immediately prior to and after the intervention. |
| Change in perception of uncertainty | "How certain are you that Zenova will work for Alex?" 4-point Likert scale for perception of uncertainty: very uncertain; somewhat uncertain; somewhat certain; very certain. | Immediately prior to and after the intervention. |
| Change in emotions | If you were Alex, how worried would you feel about taking Zenova? 4-point Likert scale for worry: extremely worried; slightly worried; not very worried; not worried at all. | Immediately prior to and after the intervention. |
| Trust | To what extent do you think the information about Zenova is trustworthy? 4-point Likert scale: not at all trustworthy; somewhat untrustworthy; somewhat trustworthy; very trustworthy. To what extent do you think the FDA, who approved Zenova and produced this information, is trustworthy? 4-point Likert scale: not at all trustworthy; somewhat untrustworthy; somewhat trustworthy; very trustworthy. Did learning about these uncertainties with Zenova make you more or less trusting of the FDA? 4-point Likert scale: less trusting, somewhat less trusting, somewhat more trusting, more trusting. | Immediately prior to and after the intervention. |
| Jul 17, 2025 |
| Prot_SAP_ICF_000.pdf |
| ID | Term |
|---|---|
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D035061 | Control Groups |
| ID | Term |
|---|---|
| D015340 | Epidemiologic Research Design |
| D004812 | Epidemiologic Methods |
| D008919 | Investigative Techniques |
| D012107 | Research Design |
| D008722 | Methods |
Not provided
Not provided